Grocer banner

GlaxoSmithKline (GSK)

Share Price:
Up 1,691.20p
Change Today:
15.20p
Market Cap:
84,364m

GlaxoSmithKline HIV treatment gets European Commission marketing approval

03 Jul 19

LONDON (ShareCast) - (Sharecast News) - GlaxoSmithKline's investee company, ViiV Healthcare, has received European Commission marketing authorisation for Dovato, which treats HIV-1 in adults and adolescents.
Dovato is a two-drug regimen of dolutegravir and lamivudine contained in a single, once-daily pill that would represent a simplification of standard European treatment of HIV.

Deborah Waterhouse, chief executive of ViiV, said: "For many years, the standard of care for treatment-nave people living with HIV in Europe has been a three-drug regimen. The data from our dolutegravir-based two-drug regimen development programme challenges this, and with the authorisation of Dovato, people living with HIV can for the first time start treatment on a once-daily, single-pill, two-drug regimen with the knowledge that efficacy is non-inferior to a three-drug regimen whilst containing fewer antiretrovirals."

The authorisation was won on the basis of studies involving more than 1,400 adults with HIV-1, which demonstrated that the drug was no less effective than the standard three-drug regimen.

Dovato was authorised by the US Food and Drug Administration in April, and further regulatory applications have been submitted worldwide.

ViiV Healthcare is a global specialist HIV company established in November 2009 by GlaxoSmithKline, its majority owner, and Pfizer, with the venture dedicated to advancing treatment and care for people with HIV.

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

 

Market Data

Currency UK Pounds
Price 1,691.20p
Change Today 15.20p
52 Week High 1,730.00p
52 Week Low 1,418.00p
Volume 5,629,496
Shares Issued 4,988.42m
Market Cap 84,364m

Dividends

  Latest Previous
  Q2 Q1
Ex-Div 08-Aug-19 16-May-19
Paid 10-Oct-19 11-Jul-19
Amount 19.00p 19.00p